Maxima Corp. v. Cystic Fibrosis Foundation

568 A.2d 1170, 81 Md. App. 602, 1990 Md. App. LEXIS 19
CourtCourt of Special Appeals of Maryland
DecidedFebruary 6, 1990
Docket696, September Term, 1989
StatusPublished
Cited by15 cases

This text of 568 A.2d 1170 (Maxima Corp. v. Cystic Fibrosis Foundation) is published on Counsel Stack Legal Research, covering Court of Special Appeals of Maryland primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Maxima Corp. v. Cystic Fibrosis Foundation, 568 A.2d 1170, 81 Md. App. 602, 1990 Md. App. LEXIS 19 (Md. Ct. App. 1990).

Opinion

GARRITY, Judge.

This appeal involves a dispute over the provisions and implementation of a lease. The parties are 6933 Arlington Development Limited Partnership (hereinafter “Arlington”), the lessor, The Maxima Corporation (hereinafter “Maxi-ma”), an assignee of the original lessee, and Cystic Fibrosis Foundation (hereinafter “Cystic”), a subtenant of Maxima. By order of March 7, 1989, the Circuit Court for Montgomery County (Raker, J.) found that Maxima had breached its lease with Arlington, and ordered it to pay damages to both Arlington and Cystic. Each party raises several questions for our consideration:

MAXIMA’S QUESTIONS

I. Whether the court erred in finding Maxima in breach of the lease and liable for damages;

II. Whether the court erred in its measure of damages;

ARLINGTON’S QUESTIONS

III. Whether the court erred in allowing Cystic to remain in possession of the leased premises despite its finding that Maxima breached the lease;

IV. Whether the court erred in denying Arlington’s claim against Cystic for hold over rent;

*606 V. Whether the court erred in denying Arlington’s claim for refund of incentive payments made pursuant to the lease;

CYSTIC’S QUESTIONS

VI. Whether the court erred in denying Cystic’s claims against Maxima for attorneys’ fees and costs; and

VII. Whether the court erred in denying Cystic’s claim against Arlington for $170,000.00 in damages.

FACTUAL BACKGROUND

On March 11, 1986, Arlington entered into a lease and addendum to lease (collectively referred to herein as “Master Lease”) with Technassociates, Inc. (hereinafter “TI”) for Arlington’s building then under construction at 6931 Arlington Boulevard, Bethesda, Maryland. The premises leased were the entire second floor of the building (“Suite 200”) and approximately 5000 square feet in the basement of the building (Space “T100”). Arlington and TI agreed on specifications for the construction of both spaces, and construction began on Suite 200. Completion was initially scheduled for August, 1986 but later moved to September, 1986.

Because Arlington considered Suites 200 and T100 difficult to rent, it offered TI various incentives to enter into the lease. 1 Among them, Arlington agreed to waive the first six months of rent; to pay $260,000.00 to Technassociates as a “Signing Payment” upon execution of the lease; to pay $260,000.00 as an “Occupancy Payment” upon TI’s occupying the premises; and to pay a final $200,000.00 as an “Anniversary Payment” on the first anniversary of the commencement of the leased term.

In accordance with the lease, Arlington paid TI the Signing Payment. In May, 1986, Arlington also began preparing the leased premises for occupancy. Work continued on *607 both the second floor and the basement until the end of June 1986. At that time, a representative of Maxima contacted Joel Fernebok, general partner of Arlington, and told him that Maxima had acquired TI and TI’s interest in the lease, and that Maxima did not know if it would be moving into the leased premises. At that point, June 30, 1986, Arlington stopped preparation of the premises, leaving both suites approximately half completed.

TI then requested that Arlington consent to an assignment of the lease to Maxima and to a subletting of Suite 200 to the Cystic Fibrosis Foundation. In mid-July Arlington received an initial set of revised plans for Cystic’s use of Suite 200. Those plans were finalized in mid-August, after which Arlington resumed preparation of Suite 200 alone. In a letter dated September 4, 1986, Arlington consented to a subletting of Suite 200 by Maxima to Cystic. On September 18, 1986, Maxima and Cystic entered into a “Sublease Agreement” which pertained only to Suite 200 and contained a termination date of August 31, 1992.

When Cystic moved into Suite 200 on October 3, 1986, Maxima demanded the $260,000.00 Occupancy Payment from Arlington. Arlington maintained that it was not obligated to make the payment because the T100 space remained unoccupied. Arlington further determined that Maxima was responsible for a 30-day delay in occupancy of the premises leased to Cystic. It offered Maxima part of the Occupancy Payment, nevertheless, if Maxima would acknowledge responsibility for the 30-day delay. In a November, 1986 letter Arlington tendered to Maxima a $204,441.55 check, the negotiability of which was conditioned on Maxima signing an attached addendum to the lease recognizing September 3, 1986 as the commencement date of the lease. Arlington sought such a recognition to establish that the rent payments for the entire leased premises would begin March 3, 1987 (following the six month waiver period). Maxima negotiated Arlington’s check but *608 did not sign the attached addendum. 2

On November 11, 1986, Maxima Vice President and General Counsel David R. Smith wrote the following to Arlington’s counsel:

Please be advised that TI/Maxima intends on occupying the 5000 square feet of space at the Leased Premises not sublet to Cystic on or about December 15,1986. We have reviewed the Premises and noted that a substantial amount of work is yet to be done in order to effect occupancy. We believe that work must commence immediately.

On December 23, 1986, however, a Maxima representative offered Arlington $175,000.00 in consideration for being released from its obligations with regard to T100, an offer that Arlington rejected. In May, 1987 Maxima notified Arlington that, “[s]ince [Arlington] has stopped work on Suite T100, it is our belief that [Arlington] has breached [Arlington’s] obligation to complete said suite in a timely manner; thus, we do not feel obligated to accept the premises if completed.” Maxima qualified this position in June, 1987, however, by a letter that stated inter alia, “Maxima offers the same buy-out proposal it made previously.”

In July, 1987, Arlington completed preparation of T100 pursuant to TI’s original plans. By letter of July 7, 1987, Arlington notified Maxima that T100 was ready for occupancy. When Maxima did not occupy and pay rent for T100 by August, 1987, Arlington advised Maxima that it was in default of the lease and that Maxima had ten days in which to cure its default. In September, 1987, Maxima proposed a sublease of Suite T100 to Cystic, and in a letter of September 10, 1987, represented the following:

*609 Please be advised that tenant intends to be responsible for Suite T100 and honor our responsibilities and obligations as set forth in the Lease as of the date of the signing of the Sublease of T100 with Cystic Fibrosis Foundation contingent upon the Landlord’s consent to the Sublease of Suite T100 with Cystic Fibrosis Foundation.

Arlington rejected this proposal, and on September 21, 1987, notified Maxima of a failure to cure the default that, in its view, entitled it to terminate the lease and hence Maxima’s right to occupy the leased premises.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Van Sloun v. Agans Bros., Inc.
778 N.W.2d 174 (Supreme Court of Iowa, 2010)
Mikeron, Inc. v. Exxon Co., U.S.A.
264 F. Supp. 2d 268 (D. Maryland, 2003)
Hannon v. Exxon Co., USA
54 F. Supp. 2d 485 (D. Maryland, 1999)
Nicholson Air v. Board of County Commissioners of Allegany County
706 A.2d 124 (Court of Special Appeals of Maryland, 1998)
Fairfax Savings, F.S.B. v. Weinberg & Green
685 A.2d 1189 (Court of Special Appeals of Maryland, 1996)
Lemley v. Lemley
675 A.2d 596 (Court of Special Appeals of Maryland, 1996)
Ernst Home Center, Inc. v. Sato
910 P.2d 486 (Court of Appeals of Washington, 1996)
Kilsheimer v. Davis
665 A.2d 723 (Court of Special Appeals of Maryland, 1995)
Marsh v. Loffler Housing Corp.
648 A.2d 1081 (Court of Special Appeals of Maryland, 1994)
Maxima Corp. v. 6933 Arlington Development Ltd. Partnership
641 A.2d 977 (Court of Special Appeals of Maryland, 1994)
Noffsinger v. Noffsinger
620 A.2d 415 (Court of Special Appeals of Maryland, 1993)
Reisterstown Plaza Associates v. General Nutrition Center, Inc.
597 A.2d 1049 (Court of Special Appeals of Maryland, 1991)
Cutler v. Sugarman Organization, Ltd.
596 A.2d 105 (Court of Special Appeals of Maryland, 1991)

Cite This Page — Counsel Stack

Bluebook (online)
568 A.2d 1170, 81 Md. App. 602, 1990 Md. App. LEXIS 19, Counsel Stack Legal Research, https://law.counselstack.com/opinion/maxima-corp-v-cystic-fibrosis-foundation-mdctspecapp-1990.